sabatolimab + azacitidine + venetoclax

**Sabatolimab + azacitidine + venetoclax** is an investigational combination therapy studied in adults with high or very high risk myelodysplastic syndrome (MDS) not suitable for intensive chemotherapy or stem cell transplant. - **Sabatolimab** is a monoclonal antibody that inhibits T cell immunoglobulin and mucin-domain containing protein-3 (TIM-3), an immune checkpoint on myeloid and lymphoid cells, aiming to enhance anti-tumor immune responses and modulate leukemic stem cells[2][4][6]. - **Azacitidine** is a hypomethylating agent (cytidine analog) that incorporates into DNA and RNA, leading to DNA hypomethylation and cytotoxicity in abnormal hematopoietic cells[1]. - **Venetoclax** is a selective small molecule BCL-2 inhibitor that induces apoptosis in malignant cells by targeting the anti-apoptotic protein BCL-2[1]. This triple combination was evaluated in a Phase II clinical trial to assess safety and efficacy; however, the study was terminated early and only a small cohort was enrolled[3][4][5][7].

Brand names

No unique brand name for the combination itself

Other names

sabatolimab + azacitidine + venetoclax